title: [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
abstract: A 74-year-old female with relapsed multiple myeloma was treated with twice-weekly bortezomib plus dexamethasone (BD)therapy, but severe gastrointestinal adverse events(grade 3 paralytic ileus and constipation)developed. After changing to once-weekly BD therapy, ≥ grade 3 gastrointestinal adverse events did not develop, and she was able to continue BD therapy. A complete response and a treatment-free interval ≥ 2 years were obtained by 8 courses of BD therapy. This case report suggests that once-weekly BD therapy may reduce severe gastrointestinal adverse events without decreasing the clinical efficacy for multiple myeloma.
authors.affiliation: Department of Hematology and Immunology, Kanazawa Medical University.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Fukushima
authors.forename: Haruka
authors.initials: H
authors.lastname: Iwao
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Sakai
authors.forename: Tomomi
authors.initials: T
authors.lastname: Sato
authors.forename: Takuji
authors.initials: T
authors.lastname: Nakamura
authors.forename: Akio
authors.initials: A
authors.lastname: Nakajima
authors.forename: Miyuki
authors.initials: M
authors.lastname: Miki
authors.forename: Toshioki
authors.initials: T
authors.lastname: Sawaki
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Fujita
authors.forename: Masao
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Masaki
authors.forename: Hisanori
authors.initials: H
authors.lastname: Umehara
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003248:Constipation / Q000139:chemically induced; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007418:Intestinal Pseudo-Obstruction / Q000139:chemically induced; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone